Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Celldex Therapeutics, Inc. - Common Stock (NQ:CLDX)

26.94 +0.66 (+2.51%)
Streaming Delayed Price Updated: 12:32 PM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 165,073
Open 26.52
Bid (Size) 26.91 (300)
Ask (Size) 26.97 (100)
Prev. Close 26.28
Today's Range 26.37 - 27.71
52wk Range 14.40 - 30.50
Shares Outstanding 66,344,236
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-0.3%
-0.3%
1 Month
-9.6%
-9.6%
3 Month
+2.7%
+2.7%
6 Month
+26.3%
+26.3%
1 Year
+1.4%
+1.4%

More News

Read More
News headline image
Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tech Rallies, Palantir Jumps 6% As Shutdown End Looms: What's Moving Markets Monday? ↗
Via Benzinga
News headline image
Celldex to Present at Upcoming Investor Conferences
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Presents Additional Positive Data Demonstrating Barzolvolimab’s Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) Study
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20 Week Placebo Controlled Treatment Period; Up to 66% of Patients
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Analyst Expectations For Celldex Therapeutics's Future ↗
Via Benzinga
News headline image
Technical Breakout Setup for CELLDEX THERAPEUTICS INC (NASDAQ:CLDX) ↗
Via Chartmill
News headline image
5 Analysts Assess Celldex Therapeutics: What You Need To Know ↗
Via Benzinga
News headline image
Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Via Benzinga
News headline image
Celldex Therapeutics Pulls Plug On Eosinophilic Esophagitis Investigational Drug As Data Falls Short ↗
Via Benzinga
News headline image
What Analysts Are Saying About Celldex Therapeutics Stock ↗
Via Benzinga
News headline image
La-Z-Boy Posts Downbeat Q1 Results, Joins James Hardie Industries, Alcon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
Why Are Celldex Shares Tumbling After Hours? ↗
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Via Benzinga
News headline image
These stocks are moving in today's after hours session ↗
Via Chartmill
News headline image
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
Via Benzinga
News headline image
Celldex Therapeutics Inc (NASDAQ:CLDX) Q2 2025 Earnings: Revenue Misses, EPS Narrowly Beats Amid Strong Pipeline Progress ↗
Via Chartmill

Frequently Asked Questions

Is Celldex Therapeutics, Inc. - Common Stock publicly traded?
Yes, Celldex Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Celldex Therapeutics, Inc. - Common Stock trade on?
Celldex Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Celldex Therapeutics, Inc. - Common Stock?
The ticker symbol for Celldex Therapeutics, Inc. - Common Stock is CLDX on the Nasdaq Stock Market
What is the current price of Celldex Therapeutics, Inc. - Common Stock?
The current price of Celldex Therapeutics, Inc. - Common Stock is 26.94
When was Celldex Therapeutics, Inc. - Common Stock last traded?
The last trade of Celldex Therapeutics, Inc. - Common Stock was at 01/07/26 12:32 PM ET
What is the market capitalization of Celldex Therapeutics, Inc. - Common Stock?
The market capitalization of Celldex Therapeutics, Inc. - Common Stock is 1.79B
How many shares of Celldex Therapeutics, Inc. - Common Stock are outstanding?
Celldex Therapeutics, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.